Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals Plc    HIK   GB00B0LCW083

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : Agrees Licensing Pact with Orion for Easyhaler

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/13/2017 | 10:44am CET

LONDON--Hikma Pharmaceuticals PLC (HIK.LN) said Monday it has signed an exclusive licensing and distribution agreement with Finnish pharmaceutical company Orion Corporation, for Orion's new Easyhaler combination product, a dry powder inhaler, for the treatment of asthma and chronic obstructive pulmonary disease.

The agreement gives Hikma the exclusive rights to register, distribute, market and sell the product in all of its Middle East and North Africa or MENA markets.

Hikma shares at 0925 GMT up 14 pence, or 0.7%, at GBP19.51, valuing the company at GBP4.68 billion.

-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS PLC
02/13DJHIKMA PHARMACEUTICALS : Agrees Licensing Pact with Orion for Easyhaler
02/13 TOP NEWS : Hikma Strikes Deal With Finland's Orion For Easyhaler
02/10 HIKMA PHARMACEUTICALS : *goldman cuts hikma pharmaceutical price target to 2400 ..
02/09 HIKMA PHARMACEUTICALS : Society conducts free physiotherapy check-ups for autist..
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
01/30 As Teva wins U.S. approval for GSK Advair copy, main fight yet to come
01/23 HIKMA PHARMACEUTICALS : British stocks gain on Wednesday
01/19 HIKMA PHARMACEUTICALS : receives approval for Sodium Oxybate Oral Solution
01/18 HIKMA PHARMACEUTICALS : Gets US Approval For Generic Cataplexy Drug
01/17 HIKMA PHARMACEUTICALS : *jefferies raises hikma pharmaceutical price target to 2..
More news
Sector news : Pharmaceuticals - NEC
08:25aDJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/01 Teva's $1bn Copaxone Blow
2016 Emerging Markets Shake Off Brexit
2016 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2016 Results - Earning..
2016 Hikma Pharmaceuticals reports H1'16 results
2016 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q4 2015 Results - Earning..
Advertisement
Financials ($)
Sales 2016 1 948 M
EBIT 2016 368 M
Net income 2016 156 M
Debt 2016 679 M
Yield 2016 0,88%
P/E ratio 2016 34,12
P/E ratio 2017 19,95
EV / Sales 2016 3,46x
EV / Sales 2017 2,93x
Capitalization 6 058 M
More Financials
Chart HIKMA PHARMACEUTICALS PLC
Duration : Period :
Hikma Pharmaceuticals Plc Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 28,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Samih Said Samih Darwazah Chairman & Chief Executive Officer
Khalid Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Ragheb Al-Shakhshir Vice President-Research & Development
Michael Richard Dwyer Ashton Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS ..7.45%6 095
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results